Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in mice

Brain Research Bulletin

Volumn 82, Issue 3-4, 2010, Pages 184-187

  Miller, Jonathan S ^a   Tallarida, Ronald J ^a   Unterwald, Ellen M ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Activity; Ambulation; Dopamine; Glycogen synthase kinase 3; Stereotypy

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; GLYCOGEN SYNTHASE KINASE 3; SODIUM CHLORIDE; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; SK&F 82958;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HYPERACTIVITY; MALE; MOBILIZATION; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIZATION; SIGNAL TRANSDUCTION; STEREOTYPY; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; HYPERKINESIA; METABOLISM; MOTOR ACTIVITY;

ANIMALS; BEHAVIOR, ANIMAL; BENZAZEPINES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; HYPERKINESIS; INDOLES; MALE; MALEIMIDES; MICE; MOTOR ACTIVITY; RECEPTORS, DOPAMINE D1;

EID: 77953537203     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2010.03.005     Document Type: Article

References (26)

1. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(14):5099-5104.
2. Beaulieu J.M., Tirotta E., Sotnikova T.D., Masri B., Salahpour A., Gainetdinov R.R., Borrelli E., Caron M.G. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J. Neurosci. 2007, 27(4):881-885.
3. Brami-Cherrier K., Valjent E., Garcia M., Pages C., Hipskind R.A., Caboche J. Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J. Neurosci. 2002, 22(20):8911-8921.
4. Cabib S., Castellano C., Cestari V., Filibeck U., Puglisi-Allegra S. D1 and D2 receptor antagonists differently affect cocaine-induced locomotor hyperactivity in the mouse. Psychopharmacology (Berl.) 1991, 105(3):335-339.
5. Chen G., Huang L.D., Jiang Y.M., Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 1999, 72(3):1327-1330.
6. Chen P.C., Lao C.L., Chen J.C. Dual alteration of limbic dopamine D1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D3 receptor mutants during the development of methamphetamine sensitization. J. Neurochem. 2007, 100(1):225-241.
7. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee Cox L., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., Holder J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7(10):793-803.
8. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43(7):1158-1164.
9. Desai R.I., Terry P., Katz J.L. A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice. Pharmacol. Biochem. Behav. 2005, 81(4):843-848.
10. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379(6566):606-612.
11. Gould T.D., Einat H., Bhat R., Manji H.K. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 2004, 7(4):387-390.
12. Grimes C.A, Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65(4):391-426.
13. Halberda J.P., Middaugh L.D., Gard B.E., Jackson B.P. DAD1- and DAD2-like agonist effects on motor activity of C57 mice: differences compared to rats. Synapse 1997, 26(1):81-92.
14. Kebabian J.W., Petzold G.L., Greengard P. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the " dopamine receptor" Proc. Natl. Acad. Sci. U.S.A. 1972, 69(8):2145-2149.
15. Konradi C, Cole R.L., Heckers S., Hyman S.E. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J. Neurosci. 1994, 14(9):5623-5634.
16. Kozikowski A.P., Gaisina I.N., Yuan H., Petukhov P.A., Blond S.Y., Fedolak A., Caldarone B., McGonigle P. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-3beta therapies for bipolar disorders. J. Am. Chem. Soc. 2007, 129(26):8328-8332.
17. Leroy K., Brion J.P. Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J. Chem. Neuroanat. 1999, 16(4):279-293.
18. Mansour A., Meador-Woodruff J.H., Zhou Q.Y., Civelli O., Akil H., Watson S.J. A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience 1991, 45(2):359-371.
19. Meyer M.E., Shults J.M. Dopamine D1 receptor family agonists, SK&F38393, SK&F77434, and SK&F82958, differentially affect locomotor activities in rats. Pharmacol. Biochem. Behav. 1993, 46(2):269-274.
20. Miller J.S., Tallarida R.J., Unterwald E.M. Cocaine-induced hyperactivity and sensitization are dependent upon GSK3. Neuropharmacology 2009, 56(8):1116-1123.
21. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78(1):189-225.
22. O'Boyle K.M., Gaitanopoulos D.E., Brenner M., Waddington J.L. Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor. Neuropharmacology 1989, 28(4):401-405.
23. Sibley D.R., Monsma F.J., Shen Y. Molecular neurobiology of dopaminergic receptors. Int. Rev. Neurobiol. 1993, 35:391-415.
24. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., Greengard P. Diverse psychotomimetics act through a common signaling pathway. Science 2003, 302:1412-1414.
25. Tallarida R.J. Drug Synergism and Dose-Effect Data Analysis 2000, CRC/Chapman and Hall, Boca Raton.
26. Weiner D.M., Levey A.I., Sunahara R.K., Niznik H.B., O'Dowd B.F., Seeman P., Brann M.R. D1 and D2 dopamine receptor mRNA in rat brain. Proc. Natl. Acad. Sci. U.S.A. 1991, 88(5):1859-1863.